CN109071668B - 抗n-乙酰基葡萄糖胺和n-乙酰基-半乳糖胺的抗体 - Google Patents

抗n-乙酰基葡萄糖胺和n-乙酰基-半乳糖胺的抗体 Download PDF

Info

Publication number
CN109071668B
CN109071668B CN201780008964.2A CN201780008964A CN109071668B CN 109071668 B CN109071668 B CN 109071668B CN 201780008964 A CN201780008964 A CN 201780008964A CN 109071668 B CN109071668 B CN 109071668B
Authority
CN
China
Prior art keywords
antibody
seq
cancer
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780008964.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN109071668A (zh
Inventor
王慧茹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huirui Biopharma Co ltd
Original Assignee
Huirui Biopharma Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huirui Biopharma Co ltd filed Critical Huirui Biopharma Co ltd
Publication of CN109071668A publication Critical patent/CN109071668A/zh
Application granted granted Critical
Publication of CN109071668B publication Critical patent/CN109071668B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
CN201780008964.2A 2016-02-19 2017-02-17 抗n-乙酰基葡萄糖胺和n-乙酰基-半乳糖胺的抗体 Active CN109071668B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/074146 2016-02-19
PCT/CN2016/074146 WO2017139975A1 (en) 2016-02-19 2016-02-19 Antibodies against n-acetylglucosamine and n-acetyl-galactosamine
PCT/CN2017/073890 WO2017140256A1 (en) 2016-02-19 2017-02-17 Antibodies against n-acetylglucosamine and n-acetyl-galactosamine

Publications (2)

Publication Number Publication Date
CN109071668A CN109071668A (zh) 2018-12-21
CN109071668B true CN109071668B (zh) 2022-09-02

Family

ID=59624718

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780008964.2A Active CN109071668B (zh) 2016-02-19 2017-02-17 抗n-乙酰基葡萄糖胺和n-乙酰基-半乳糖胺的抗体

Country Status (4)

Country Link
US (2) US11446328B2 (enExample)
JP (1) JP6972030B2 (enExample)
CN (1) CN109071668B (enExample)
WO (2) WO2017139975A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113101294A (zh) 2013-03-15 2021-07-13 杭州惠瑞生物医药有限公司 感染相关疾病或病症的生物治疗产品
WO2016026143A1 (en) 2014-08-22 2016-02-25 Huiru Wang Saccharide-based biomarkers and therapeutics
WO2017139975A1 (en) 2016-02-19 2017-08-24 Huiru Wang Antibodies against n-acetylglucosamine and n-acetyl-galactosamine
SG11202103124WA (en) * 2018-10-23 2021-04-29 Glycardial Diagnostics S L Antibodies specific for glycosylated apoj and uses thereof
KR102800844B1 (ko) * 2019-02-18 2025-04-29 가부시키가이샤 에누비 켄코우겡큐쇼 세포의 선발 방법, 핵산의 제조 방법, 재조합 세포의 제조 방법, 목적 물질의 제조 방법, 의약 조성물의 제조 방법, 및 시약
CN111234022B (zh) * 2019-12-16 2024-03-22 江苏省药物研究所有限公司 抗n-乙酰氨基葡萄糖转移酶修饰的蛋白质单克隆抗体及杂交瘤细胞株和其制备方法与应用
WO2025090749A1 (en) * 2023-10-25 2025-05-01 St. Jude Children's Research Hospital, Inc. Chimeric antigen receptors targeting leucine rich repeat containing 15 (lrrc15)
CN118891290A (zh) * 2024-04-12 2024-11-01 科济生物医药（上海）有限公司 细胞免疫疗法的组合物和方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0390115A1 (en) * 1989-03-29 1990-10-03 Ikuo Yamashina Monoclonal antibody NNY128
WO2011054359A2 (en) * 2009-11-06 2011-05-12 University Of Copenhagen Method for early detection of cancer
CN102178686A (zh) * 2010-01-07 2011-09-14 王慧茹 多糖相关疾病的药物和疫苗及免疫测定产品
CN107074960A (zh) * 2014-08-22 2017-08-18 王慧茹 基于糖类的生物标记物和治疗剂

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1990002761A1 (fr) 1988-09-14 1990-03-22 Teijin Limited Anticorps monoclonal humain et procede de preparation
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
WO2004017810A2 (en) * 2002-08-20 2004-03-04 Biotie Therapies Corp. Tumor specific oligosaccharide epitopes and use thereof
DE10303664A1 (de) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
AU2004294526A1 (en) * 2003-12-03 2005-06-16 Glycominds, Ltd Method for diagnosing diseases based on levels of anti-glycan antibodies
WO2008055242A2 (en) * 2006-11-01 2008-05-08 The Johns Hopkins University Early detection of diabetes
US20090324617A1 (en) 2008-01-24 2009-12-31 Glykos Finland Ltd. Cancer specific glycans and use thereof
US9119866B2 (en) * 2008-04-08 2015-09-01 Huiru Wang Glycan-based drugs, therapies and biomarkers
US8722856B2 (en) * 2008-10-28 2014-05-13 National University Corporation Hokkaido University Anti-MUC1 antibody
US8957188B2 (en) * 2009-04-01 2015-02-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that bind GalNAc1-3Gal, pharmaceutical compositions and methods of using same
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
JP5916017B2 (ja) * 2010-04-28 2016-05-11 塩野義製薬株式会社 新規なｍｕｃ１抗体
CN102372773B (zh) * 2010-08-11 2013-06-05 中国科学院生物物理研究所 人膀胱癌肿瘤标志物及其抗体和应用
US20140323324A1 (en) * 2010-12-16 2014-10-30 National Institute Of Advanced Industrial Science And Technology Method for Enrichment and Separation of Spinal Fluid Glycoprotein, Method for Searching for Marker for Central Nervous System Diseases Which Utilizes the Aforementioned Method, and Marker for Central Nervous System Diseases
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
US10317409B2 (en) * 2013-03-01 2019-06-11 Detroit R&D, Inc. Glycosylation site-specific antibodies and anti-cancer compounds
WO2014159244A2 (en) * 2013-03-14 2014-10-02 Merck Patent Gmbh O-GlcNAc TAU ANTIBODY AND USE THEREOF
EP2970272B1 (en) * 2013-03-14 2019-02-27 Merck Patent GmbH Glycosidase inhibitors
JP6750148B2 (ja) * 2014-04-25 2020-09-02 公益財団法人野口研究所 糖鎖切断抗体の製造方法及び均一糖鎖抗体
CN104267185B (zh) 2014-09-12 2016-05-18 范飞舟 检测肿瘤的试剂盒及其专用识别n-乙酰氨基葡萄糖的物质
CN104198707B (zh) * 2014-09-12 2016-09-14 范飞舟 N-乙酰氨基葡萄糖在制备检测肿瘤的试剂盒中的应用
CN105177031B (zh) * 2015-06-12 2018-04-24 北京艺妙神州医疗科技有限公司 嵌合抗原受体修饰的t细胞及其用途
WO2017139975A1 (en) 2016-02-19 2017-08-24 Huiru Wang Antibodies against n-acetylglucosamine and n-acetyl-galactosamine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0390115A1 (en) * 1989-03-29 1990-10-03 Ikuo Yamashina Monoclonal antibody NNY128
WO2011054359A2 (en) * 2009-11-06 2011-05-12 University Of Copenhagen Method for early detection of cancer
CN102178686A (zh) * 2010-01-07 2011-09-14 王慧茹 多糖相关疾病的药物和疫苗及免疫测定产品
CN107074960A (zh) * 2014-08-22 2017-08-18 王慧茹 基于糖类的生物标记物和治疗剂

Also Published As

Publication number Publication date
WO2017140256A1 (en) 2017-08-24
JP6972030B2 (ja) 2021-11-24
JP2019513410A (ja) 2019-05-30
US20190038669A1 (en) 2019-02-07
CN109071668A (zh) 2018-12-21
US11446328B2 (en) 2022-09-20
WO2017139975A1 (en) 2017-08-24
US20230065536A1 (en) 2023-03-02
US12391766B2 (en) 2025-08-19

Similar Documents

Publication Publication Date Title
CN109071668B (zh) 抗n-乙酰基葡萄糖胺和n-乙酰基-半乳糖胺的抗体
CN104662044B (zh) 用于治疗ror1癌症并抑制转移的抗体和疫苗
TWI708788B (zh) 雙特異性抗體
US11919968B2 (en) Methods of treating gastrointestinal diseases characterized by inflammatory cells
CN101820910B (zh) 结合细胞内prl-1多肽或prl-3多肽的抗体
US20230391886A1 (en) Compositions and methods for muc18 targeting
JP2022523333A (ja) 抗ｇａｌ３抗体およびその使用
Ho et al. A novel high‐affinity human monoclonal antibody to mesothelin
CN109988240B (zh) 抗gpc-3抗体及其用途
WO2021053199A1 (en) Single-domain antibodies directed against lilrb2
JP2018518474A (ja) グリピカン−３に対する抗体並びにがん診断及び治療におけるそれらの使用
CN117794571A (zh) 抗癌和免疫增强的新靶点
US10829560B2 (en) Agents binding specifically to human cadherin-17, human cadherin-5, human cadherin-6 and human cadherin-20 RGD motif
TWI862019B (zh) 治療性ｃｄ２４人類化單株抗體及抗腫瘤轉譯應用
US20110300068A1 (en) Agent for prophylaxis or treatment of cancer
HK1252633B (en) Antibodies binding to an intracellular prl-1 or prl-3 polypeptide

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant